Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 37

Sort by

Sort Order Select

Journal Articles

Prospective predictors of toxicity of BCMA‑directed CART therapy in multiple myeloma

Eyal Lebel, Shlomit Kfir-Erenfeld, Nathalie Asherie, Shlomo Elias, Sigal Grisariu, Batia Avni, Lyudmila Rheingold, Ekaterina Dikhter, Marina Krizhevskaya, Netanel Chendler, Eran Zimran, Vladimir Vainstein, Shlomzion Aumann, Shlomit Herr, Miri Assayag, Moshe Gatt, Polina Stepensky, Ora Paltiel

Blood (2025) 146 (Supplement 1): 4155.

https://doi.org/10.1182/blood-2025-4155

Published: 2025

Journal Articles

Summary analysis of the phase 1a/b study with HBI0101, an academic anti-BCMA chimeric antigen receptor T-cell (CART) for relapsed/refractory multiple myeloma

Eyal Lebel, Nathalie Asherie, Shlomit Kfir-Erenfeld, Batia Avni, Sigal Grisariu, Shlomo Elias, Eran Zimran, Vladimir Vainstein, Shlomzion Aumann, Miri Assayag, Marina Krizhevskaya, Ekaterina Dikhter, Marjorie Pick, Yaël Cohen, Irit Avivi, Cyrille Cohen, Moshe Gatt, Polina Stepensky

Blood (2025) 146 (Supplement 1): 2379.

https://doi.org/10.1182/blood-2025-2379

Published: 2025

Journal Articles

BCMA-targeted CAR T-cell therapy in refractory autoimmune diseases: Initial Results from a Phase 1 clinical trial

Blood (2025) 146 (Supplement 1): 2378.

https://doi.org/10.1182/blood-2025-2378

Published: 2025

Journal Articles

Allogeneic hematopoietic cell transplantation in dyskeratosis congenita: Short and long- term outcome of 183 consecutive patients transplanted at EBMT centers

Blood (2025) 146 (Supplement 1): 2490.

https://doi.org/10.1182/blood-2025-2490

Published: 2025

Journal Articles

Comparable outcomes of haploidentical, sibling, and unrelated donor transplantation for adult T-ALL in second remission: a study from the global committee and ALWP of the EBMT

Blood (2025) 146 (Supplement 1): 2526.

https://doi.org/10.1182/blood-2025-2526

Published: 2025

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) Outcomes in Leukocyte Adhesion Deficiency Type -I

Blood (2024) 144 (Supplement 1): 5079.

https://doi.org/10.1182/blood-2024-203643

Published: 2024

Journal Articles

Efficacy of HBI0101, an Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) for Relapsed/Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 1030.

https://doi.org/10.1182/blood-2024-198225

Published: 2024

Journal Articles

Tisagenlecleucel for the Management of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: An Interim Report of the European Post-Authorisation Safety Study Conducted By EBMT

Blood (2024) 144 (Supplement 1): 607.

https://doi.org/10.1182/blood-2024-200367

Published: 2024

Journal Articles

Efficacy and Safety of Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) for the Treatment of Relapsed and Refractory AL Amyloidosis

Blood (2024) 144 (Supplement 1): 894.

https://doi.org/10.1182/blood-2024-198256

Published: 2024

Journal Articles

Genotype-phenotype correlations in chronic granulomatous disease: insights from a large national cohort

Blood (2024) 144 (12): 1300–1313.

https://doi.org/10.1182/blood.2023022590

Published: 2024

Includes: Supplemental data

Journal Articles

Wiskott-Aldrich syndrome: a study of 577 patients defines the genotype as a biomarker for disease severity and survival

Tanja C. Vallée, Jannik S. Glasmacher, Hannes Buchner, Peter D. Arkwright, Uta Behrends, Anastasia Bondarenko, Michael J. Browning, David Buchbinder, Alessandro Cattoni, Liudmyla Chernyshova, Peter Ciznar, Theresa Cole, Wojciech Czogała, Gregor Dueckers, John David M. Edgar, Fatih Erbey, Anders Fasth, Francesca Ferrua, Renata Formankova, Eleonora Gambineri, Andrew R. Gennery, Frederick D. Goldman, Luis I. Gonzalez-Granado, Carsten Heilmann, Tarja Heiskanen-Kosma, Hanna Juntti, Leena Kainulainen, Hirokazu Kanegane, Neslihan E. Karaca, Sara S. Kilic, Christoph Klein, Sylwia Kołtan, Irina Kondratenko, Isabelle Meyts, Gulnara M. Nasrullayeva, Lucia D. Notarangelo, Srdjan Pasic, Isabelle Pellier, Claudio Pignata, Siraj Misbah, Ansgar Schulz, Gesmar R. Segundo, Anna Shcherbina, Mary Slatter, Robert Sokolic, Pere Soler-Palacin, Polina Stepensky, Joris M. van Montfrans, Samppa Ryhänen, Beata Wolska-Kuśnierz, John B. Ziegler, Xiaodong Zhao, Alessandro Aiuti, Hans D. Ochs, Michael H. Albert

Blood (2024) 143 (24): 2504–2516.

https://doi.org/10.1182/blood.2023021411

Published: 2024

Includes: Supplemental data

Journal Articles

Safety and Efficacy of a Locally Produced Novel Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) (HBI0101) for the Treatment of Relapsed and Refractory Multiple Myeloma

Eyal Lebel, Nathalie Asherie, Shlomit Kfir-Erenfeld, Batia Avni, Sigal Grisariu, Shlomo Elias, Miri Assayag, Tatyana Dubnikov, Nomi Zalcman, Marjorie Pick, Eran Zimran, Yael C. Cohen, Irit Avivi Mazza, Cyrille Cohen, Moshe E Gatt, Polina Stepensky

Blood (2023) 142 (Supplement 1): 4852.

https://doi.org/10.1182/blood-2023-185069

Published: 2023

Journal Articles

Towards a Decision Engine for Therapeutic Optimization of Relapsed Refractory Multiple Myeloma

Yael C. Cohen, Mor Zada, Shuang-Yin Wang, Assaf Weiner, Natan Melamed, Polina Stepensky, Moshe E Gatt, Shlomit Kfir-Erenfeld, Nathalie Asherie, Eyal Lebel, Irit Avivi Mazza, Anna Gurevich Shapiro, Iuliana Vaxman, Tamir Shragai, Paulina Chalan, Eyal David, Ido Amit

Blood (2023) 142 (Supplement 1): 341.

https://doi.org/10.1182/blood-2023-190178

Published: 2023

Journal Articles

Feasibility of a Novel Academic Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis

Eyal Lebel, Shlomit Kfir-Erenfeld, Nathalie Asherie, Sigal Grisariu, Batia Avni, Shlomo Elias, Miri Assayag, Tatyana Dubnikov, Nomi Zalcman, Marjorie Pick, Eran Zimran, Yael C. Cohen, Irit Avivi Mazza, Cyrille Cohen, Polina Stepensky, Moshe E Gatt

Blood (2023) 142 (Supplement 1): 538.

https://doi.org/10.1182/blood-2023-186450

Published: 2023

Journal Articles

ATG-F Versus ATG-T for Graft Versus Host Disease Prevention in Allogeneic Stem Cell Transplantation: A Retrospective Comparative Study

Itay Falicovich, Boaz Nachmias, Eran Zimran, Adir Shaulov, Moshe E Gatt, Polina Stepensky, Sigal Grisariu Greenzaid, Batia Avni

Blood (2022) 140 (Supplement 1): 12876–12877.

https://doi.org/10.1182/blood-2022-164586

Published: 2022

Journal Articles

Response Rates of Extra-Nodal Diffuse Large B Cell Lymphoma to CD19-CAR T Cells - a Real Word Retrospective Multi-Center Study

Blood (2022) 140 (Supplement 1): 3816–3817.

https://doi.org/10.1182/blood-2022-165149

Published: 2022

Journal Articles

Familial Predisposition to B-Cell Precursor Acute Lymphoblastic Leukemia Mediated By PAX5 Germline Variants

Franziska Auer, Adela Escuerdo, Ulrike Anne Friedrich, Polina Stepensky, Arndt Borkhardt, Sarah Elitzur, Masatoshi Takagi, Julia Hauer

Blood (2022) 140 (Supplement 1): 8888–8889.

https://doi.org/10.1182/blood-2022-166646

Published: 2022

Journal Articles

Tecam (Thiotepa, Etoposide, cyclophosphamide, Cytarabine and Melphalan) Is an Effective and Safe Conditioning Regimen for Autologous Transplant in Lymphoma

Yarden Cohen, Eyal Lebel, Eran Zimran, Adir Shaulov, Polina Stepensky, Sigal Grisariu Greenzaid, Batia Avni

Blood (2022) 140 (Supplement 1): 4859–4860.

https://doi.org/10.1182/blood-2022-165401

Published: 2022

Journal Articles

Chronic Graft Versus Host Disease Detected By Tissue-Specific Cell-Free DNA Methylation Biomarkers

Batia Avni, Daniel Neiman, Elior Shaked, Sigal Grisariu Greenzaid, Mona Kuzli, Andrea Fracchia, Polina Stepensky, Tsila Zuckerman, Ahinoam Lev-Sagie, Ilana Fox-Fisher, Sheina Piyanzin, Joshua Moss, Benjamin Glaser, Ruth Shemer, Yuval Dor

Blood (2022) 140 (Supplement 1): 1574–1575.

https://doi.org/10.1182/blood-2022-156740

Published: 2022

Journal Articles

Letermovir Prophylaxis for High-Risk Allogenic Transplantation Recipients, Real- World Israeli Experience

Sigal Grisariu Greenzaid, Ron Ram, Mona Kazuli, Dana Yehudai-Ofir, Liat Shargian, Tsila Zuckerman, Moshe Yeshurun, Odelia Amit, Yael Bar-On, Eran Zimran, Adir Shaulov, Polina Stepensky, Jacob Strahilevitz, Batia Avni

Blood (2022) 140 (Supplement 1): 12833–12834.

https://doi.org/10.1182/blood-2022-164694

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Prospective predictors of toxicity of BCMA‑directed CART therapy in multiple myeloma

Summary analysis of the phase 1a/b study with HBI0101, an academic anti-BCMA chimeric antigen receptor T-cell (CART) for relapsed/refractory multiple myeloma

BCMA-targeted CAR T-cell therapy in refractory autoimmune diseases: Initial Results from a Phase 1 clinical trial

Allogeneic hematopoietic cell transplantation in dyskeratosis congenita: Short and long- term outcome of 183 consecutive patients transplanted at EBMT centers

Comparable outcomes of haploidentical, sibling, and unrelated donor transplantation for adult T-ALL in second remission: a study from the global committee and ALWP of the EBMT

Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) Outcomes in Leukocyte Adhesion Deficiency Type -I

Efficacy of HBI0101, an Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) for Relapsed/Refractory Multiple Myeloma

Tisagenlecleucel for the Management of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: An Interim Report of the European Post-Authorisation Safety Study Conducted By EBMT

Efficacy and Safety of Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) for the Treatment of Relapsed and Refractory AL Amyloidosis

Genotype-phenotype correlations in chronic granulomatous disease: insights from a large national cohort

Wiskott-Aldrich syndrome: a study of 577 patients defines the genotype as a biomarker for disease severity and survival

Safety and Efficacy of a Locally Produced Novel Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) (HBI0101) for the Treatment of Relapsed and Refractory Multiple Myeloma

Towards a Decision Engine for Therapeutic Optimization of Relapsed Refractory Multiple Myeloma

Feasibility of a Novel Academic Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis

ATG-F Versus ATG-T for Graft Versus Host Disease Prevention in Allogeneic Stem Cell Transplantation: A Retrospective Comparative Study

Response Rates of Extra-Nodal Diffuse Large B Cell Lymphoma to CD19-CAR T Cells - a Real Word Retrospective Multi-Center Study

Familial Predisposition to B-Cell Precursor Acute Lymphoblastic Leukemia Mediated By PAX5 Germline Variants

Tecam (Thiotepa, Etoposide, cyclophosphamide, Cytarabine and Melphalan) Is an Effective and Safe Conditioning Regimen for Autologous Transplant in Lymphoma

Chronic Graft Versus Host Disease Detected By Tissue-Specific Cell-Free DNA Methylation Biomarkers

Letermovir Prophylaxis for High-Risk Allogenic Transplantation Recipients, Real- World Israeli Experience

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only